ArticleDrugs & aging2026
Body Mass Index Category and the Association Between Polypharmacy and Functional Recovery in Stroke Patients: A Retrospective Cohort Study.
Article in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy is a known risk factor for adverse outcomes during stroke rehabilitation; however, evidence is limited on whether nutritional status modifies this association. This study investigated whether the association between polypharmacy and functional recovery in patients after stroke differed according to body mass index (BMI), an anthropometric indicator related to nutritional status.
methodsThis retrospective cohort study included patients with stroke admitted to a convalescent rehabilitation ward in Japan between January 2015 and December 2024. Patients with cerebral infarction, intracerebral hemorrhage, or subarachnoid hemorrhage were eligible. Polypharmacy was defined as the prescription of five or more medications at admission. Patients were classified by BMI according to the criteria of the Japan Society for the Study of Obesity: underweight (< 18.5 kg/m
resultsAmong 1245 patients (median age, 75 years; 54.3% men), a significant negative interaction between polypharmacy and underweight status was observed for the FIM-motor score at discharge (B = - 4.396, 95% CI - 8.693 to - 0.100). In the underweight group, patients with polypharmacy had significantly lower adjusted FIM-motor scores than those without (65.3 versus 69.8; p = 0.020). No significant association between polypharmacy and functional recovery was found in the normal-weight or obese groups. Polypharmacy was not associated with FIM-cognitive scores or home discharge rates in any BMI category.
conclusionsPolypharmacy was associated with modestly poorer activities of daily living at discharge primarily among underweight patients after stroke. These findings suggest that BMI category may help identify patients who could benefit from closer medication assessment, although the clinical magnitude of the association was limited.
Identifiers
42550458What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.